Vimarsana
Biggest News Aggregation in the World

Sunghoon Kim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sunghoon Kim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sunghoon Kim Today - Breaking & Trending Today

Generous perks equals happy workers? Not always. Here's what employees really want - Vimarsana News

Generous perks equals happy workers? Not always. Here's what employees really want

Benefits need to meet three criteria to be most effective at attracting and retaining employees, writes Associate Professor Sunghoon Kim for The

Budget Smudgeit - Vimarsana News

Budget Smudgeit

Early comments on the budget. Basically tax cuts are being paid by more borrowing. There is no way this can be described as being fiscally neutral.

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH) - Vimarsana News

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

/PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for...

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease - Vimarsana News

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease

SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart,

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine - Vimarsana News

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Elucidated molecular mechanism behind safety and efficacy of Bersiporocin Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 26, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis...